| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/15/2013 | CN101467971B Dispersible tablet containing letrozole |
| 05/15/2013 | CN101466407B Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| 05/15/2013 | CN101019853B Composition containing dihomo-gamma-linolenic acid (DGLA) as the active ingredient |
| 05/14/2013 | US8442611 Medical device with reservoir-based sensors |
| 05/14/2013 | US8440893 Therapeutic agent for rheumatoid arthritis |
| 05/14/2013 | US8440755 Method of making hydroxyaryl-functionalized interpolymer |
| 05/14/2013 | US8440752 Coating compositions containing low VOC compounds |
| 05/14/2013 | US8440743 Non-aqueous resin emulsion is a polyacryl polyol resin; dispersion medium of aliphatic hydrocarbon and an alicyclic hydrocarbon; white ink coloring material contains a hollow resin particle emulsion; suppresses viscosity increase; excellent discharge property; fixability to a recording medium |
| 05/14/2013 | US8440703 Methods of using sustained release aminopyridine compositions |
| 05/14/2013 | US8440650 Methods of treating hypertriglyceridemia |
| 05/14/2013 | US8440628 stable aqueous solution containing endogenous growth hormone secretagogues having pH range of 2 to 7; a pH adjuster or a buffer agent; nondegradation, storage stability; biodrug inducing the secretion of growth hormone |
| 05/14/2013 | US8440619 Utilization of hypertension/hypercardia-preventing effect of D-allose |
| 05/14/2013 | US8440236 Calcium carbonate granulation |
| 05/14/2013 | US8440232 Methods of treatment using a gastric retained gabapentin dosage |
| 05/14/2013 | US8440231 Swellable particles for drug delivery |
| 05/14/2013 | US8440230 Formulation based on micronized natural calcite mineral as a plant booster and mineral fertilizer |
| 05/14/2013 | US8440229 Hollow silica nanospheres and methods of making same |
| 05/14/2013 | US8440228 Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease |
| 05/14/2013 | US8440227 Biodegradable, non-toxic biological adhesive and methods for use in abdominal surgery |
| 05/14/2013 | US8440226 Solvent/polymer solutions as suspension vehicles |
| 05/14/2013 | US8440225 Process of making flowable hemostatic compositions and devices containing such compositions |
| 05/14/2013 | US8440224 Multi-component pharmaceutical dosage form |
| 05/14/2013 | US8440223 Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers |
| 05/14/2013 | US8440222 Reservoir system with closed membrane |
| 05/14/2013 | US8440221 Transdermal drug delivery method and system |
| 05/14/2013 | US8440220 Sustained release of drug antagonist; analgesic reservoir, barrier layer |
| 05/14/2013 | US8440216 Sustained release intraocular implants and related methods |
| 05/14/2013 | US8440210 Stabilized pharmaceutical product |
| 05/14/2013 | US8440209 Adhesive for medical applications and means for haemostasis |
| 05/14/2013 | US8440182 Methods and compositions for treating phenylketonuria |
| 05/14/2013 | US8440171 Composition and its physical requirements for eliminating odors in air |
| 05/14/2013 | US8440170 Orally disintegrating tablets with speckled appearance |
| 05/14/2013 | US8439897 Assessing residual insulin time |
| 05/14/2013 | US8439896 Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| 05/14/2013 | CA2791487A1 Flexible sterile bag containing pharmaceutical products and diluant separately and method of making the same |
| 05/14/2013 | CA2734402C Nicotine-containing granulate |
| 05/14/2013 | CA2602210C Tablet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |
| 05/14/2013 | CA2602074C An aqueous polymeric system for pressure sensitive adhesive matrix preparation |
| 05/14/2013 | CA2599502C Sublingual coated tablet |
| 05/14/2013 | CA2596011C Polymer particle delivery compositions and methods of use |
| 05/14/2013 | CA2585426C A highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a powder and a freezedrying step |
| 05/14/2013 | CA2571519C Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
| 05/14/2013 | CA2568391C Coated tablet formulation and method |
| 05/14/2013 | CA2567075C Pharmaceutical suspension composition |
| 05/14/2013 | CA2563692C Compositions and methods for enhancing contrast in imaging |
| 05/14/2013 | CA2562287C Sustained-release oral molsidomine composition for treating atherosclerosis |
| 05/14/2013 | CA2552463C New compositions containing quinoline compounds |
| 05/14/2013 | CA2547446C Solid forms of anti-egfr-antibodies |
| 05/14/2013 | CA2544814C Non-symmetrical gelling agent |
| 05/14/2013 | CA2539982C Pantoprazole multiparticulate formulations |
| 05/14/2013 | CA2537477C Capsules containing active substance pellets with different release profiles |
| 05/14/2013 | CA2520521C Preserved ophthalmic compositions |
| 05/14/2013 | CA2516399C Pharmaceutical compositions of safingol and methods of using the same |
| 05/14/2013 | CA2514720C Coated particles and pharmaceutical dosage forms |
| 05/14/2013 | CA2509827C A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 05/14/2013 | CA2491136C A chemical carrier |
| 05/14/2013 | CA2465753C Orodispersible tablet having high homogeneity and the preparation method thereof |
| 05/14/2013 | CA2460352C Composition and transdermal drug delivery device |
| 05/14/2013 | CA2389487C Process for the production of a reversibly inactive acidified plasmin composition |
| 05/10/2013 | WO2013067537A1 Nanoparticle-based drug delivery |
| 05/10/2013 | WO2013067530A2 Virion derived protein nanoparticles for delivering radioisotopes for the diagnosis and treatment of malignant and systemic disease and the monitoring of therapy |
| 05/10/2013 | WO2013067347A1 Edible wafer-type product for delivery of nutraceuticals and pharmaceuticals |
| 05/10/2013 | WO2013067346A1 Dermal delivery compositions and methods |
| 05/10/2013 | WO2013067281A1 Processes for producing protein microparticles |
| 05/10/2013 | WO2013067203A1 Reprogramming of cellular adhesion |
| 05/10/2013 | WO2013067043A1 Methods for treating cancers using oral formulations of cytidine analogs |
| 05/10/2013 | WO2013067022A1 Formulations for the treatment of diabetes |
| 05/10/2013 | WO2013066903A1 Combinational liposome compositions for cancer therapy |
| 05/10/2013 | WO2013066735A1 Nano-suspension process |
| 05/10/2013 | WO2013066398A1 Use of carbon nanomaterials with antioxidant properties to treat oxidative stress |
| 05/10/2013 | WO2013066280A1 Water soluble antipsychotic formulations |
| 05/10/2013 | WO2013066279A1 Solid dosage forms comprising ezetimibe |
| 05/10/2013 | WO2013066278A1 A process for production of pharmaceutical formulations comprising nateglinide |
| 05/10/2013 | WO2013066277A1 Synergic compositions |
| 05/10/2013 | WO2013066179A1 Liposomal corticosteroids for treatment of inflammatory disorders in humans |
| 05/10/2013 | WO2013066028A1 Improved-safety entecavir-containing pharmaceutical composition and production method therefor |
| 05/10/2013 | WO2013065936A1 Complex agent containing clopidogrel and aspirin |
| 05/10/2013 | WO2013065922A1 Pharmaceutical composition including a diphenylpropenone compound as an active ingredient for preventing and treating an inflammatory disorder in the nervous system |
| 05/10/2013 | WO2013065720A1 Ophthalmological aqueous composition |
| 05/10/2013 | WO2013065719A1 Ophthalmological aqueous composition |
| 05/10/2013 | WO2013065068A1 Oral disintegrating composition of anti-histamine agents |
| 05/10/2013 | WO2013065051A1 Formulation and device for treating ceruminosis |
| 05/10/2013 | WO2013065029A1 Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections |
| 05/10/2013 | WO2013065028A1 Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections |
| 05/10/2013 | WO2013065002A1 Combination of a nanoparticle comprising a charged core made of phospholipid with a protein - use for the in vitro delivery of said protein |
| 05/10/2013 | WO2013064911A2 Single use system for sterilely producing lipid-nucleic acid particles |
| 05/10/2013 | WO2013064900A1 Oral immediate release formulations for substituted quinazolinones |
| 05/10/2013 | WO2013064853A1 Reduced dose oral pharmaceutical compositions of fenofibrate |
| 05/10/2013 | WO2013064837A1 Multisomes: encapsulated droplet networks |
| 05/10/2013 | WO2013064745A1 Osmotically active vaginal delivery system |
| 05/10/2013 | WO2013064535A1 Pharmaceutical composition of omeprazole |
| 05/10/2013 | WO2013064193A1 Pharmaceutical compositions comprising sevelamer |
| 05/10/2013 | WO2013039350A3 Skin composition for external use containing ceramides |
| 05/10/2013 | WO2013038271A4 Fill formulations and capsules and method of use to avoid migration of fill into or through the shell |
| 05/10/2013 | WO2013036309A3 Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
| 05/10/2013 | WO2013032828A3 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| 05/10/2013 | WO2013030535A3 Method of preparing carrier liquids |
| 05/10/2013 | WO2013022783A3 Progesterone containing oral dosage forms and related methods |
| 05/10/2013 | WO2013015979A3 Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) |
| 05/10/2013 | WO2013012628A3 Immune-stimulating photoactive hybrid nanoparticles |